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Abstract Axonal damage leads to permanent deficits in the
adult central nervous system (CNS) not only because of the
weak intrinsic ability of adult neurons to activate their
growth program but importantly also because of the pres-
ence of specific growth inhibitors in the CNS tissue and the
environment of the damaged axons. The well-studied
myelin-derived protein Nogo-A is involved in various cel-
lular and molecular events contributing to the failure of CNS
axons to regrow and reconnect after transection. Recent
studies have shown that, by acting in a negative way on
the cytoskeleton and on the growth program of axotomized
neurons, Nogo-A exerts fast and chronic inhibitory effects
on neurite outgrowth. On the other hand, the blockade of
Nogo-A results in a marked enhancement of compensatory
and regenerative axonal extension in vivo; this enhancement
is often paralleled by significant functional recovery, for
example, of locomotion or skilled forelimb reaching after
spinal cord or stroke lesions in rats and monkeys. Surpris-
ingly, the blockade of Nogo-A or its receptor NgR in the
hippocampus has recently been demonstrated to enhance long-
term potentiation. A role of Nogo-A in synaptic plasticity/
stability might therefore represent an additional, new and
important aspect of CNS circuit remodeling. Function-
blocking anti-Nogo-A antibodies are currently being tested
in a clinical trial for improved outcome after spinal cord
injury.
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Nogo-A protein expression in the intact and injured
central nervous system
Nogo-A is a transmembrane protein of about 1200 amino acids
(aa) including a C-terminal 200-aa reticulon (RTN) domain
(Chen et al. 2000; GrandPre et al. 2000). It has been purified
from mammalian central nervous system (CNS) myelin and is
one of themost potent neurite growth inhibitors in CNSmyelin
and tissue (Spillmann et al. 1998). Nogo-A is mainly expressed
by oligodendrocytes in the adult CNS (Huber et al. 2002;
Wang et al. 2002b). The high endogenous expression of
Nogo-A by oligodendrocytes shows little increase around a
spinal cord injury site (Huber et al. 2002). Before myelin
formation, Nogo-A is strongly expressed by developing and
immature neurons and neuronal Nogo-A persists at a high level
in plastic CNS regions such as the cortex, the hippocampus and
dorsal root ganglia (Huber et al. 2002; Peng et al. 2011). The
presence of Nogo-A in plastic areas of the adult CNS appears
paradoxical and suggests additional functions unrelated to
axonal plasticity. Nevertheless, after axonal severing in the
optic nerve, we have observed an up-regulation of Nogo-A
that is most striking in a subpopulation of retinal ganglion cells
with larger soma sizes (Pernet et al. 2011). In the pyramidal
neurons and interneurons of the cortex, increased Nogo-A
levels have been seen in stroke perilesional areas (Cheatwood
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et al. 2008). The functions of Nogo-A under these conditions
of neuronal damage are not known.
Nogo-A neutralization or knock-out or Nogo receptor
suppression enhances axonal growth after injury
The functional deficits after spinal cord injury depend on the
location and severity of the damage. In the case of an
incomplete spinal cord lesion, a spontaneous remodeling
of intraspinal circuits, e.g., by the formation of detour path-
ways, contributes to the recovery of hindlimb function
(Bareyre et al. 2004). Under more severe lesion conditions
in which recovery is not observed, the intrathecal infusion of
function-blocking anti-Nogo-A antibodies significantly
improves sensory-motor functions and stimulates axonal
sprouting from damaged and intact fibers (Thallmair et al.
1998; Raineteau et al. 2001; Liebscher et al. 2005; Freund et
al. 2006, 2009; Gonzenbach et al. 2012). Long-range axonal
regeneration and increased compensatory growth of intact
fibers have been observed after the application of various anti-
Nogo-A antibodies. A delay in the delivery of these antibodies
by 1 week but not 2 weeks, is efficient to increase cortico-
spinal tract axon regeneration over several millimeters after
dorsal thoracic spinal cord lesion (Gonzenbach and Schwab
2008). Consistent with this, hindlimb function is improved
when antibody infusion begins no later than 1 week after
injury. In contrast, in a rat stroke model, skilled forelimb
movements recover, even when anti-Nogo-A treatment is
started as late as 9 weeks after ischemic brain damage (Tsai
et al. 2011). Importantly, similar anatomical and behavioral
results have been obtained with reagents blocking the Nogo
receptor NgR1 (Li and Strittmatter 2003; Lee et al. 2004;
Wang et al. 2006, 2011), the NgR-associated protein Lingo-1
(Ji et al. 2006), or the downstream signaling components RhoA
(Dergham et al. 2002; Fournier et al. 2003; Lord-Fontaine et al.
2008) or ROCK (Fournier et al. 2003; Duffy et al. 2009). All
these findings not only establish a strong proof-of-principle for
the clinical use of Nogo-A immunotherapy in different CNS
injury types but also raise interesting questions about the
normal physiological role played by Nogo-A in the complex
CNS of higher vertebrates.
Function-blocking antibodies directed against Nogo-A
have been extensively used by our group and have allowed
us to develop a potential therapy to treat human CNS injuries
and diseases. In vivo experiments in rats and in monkeys
represent essential preclinical tests to validate the efficiency
and safety of Nogo-A antibody administration. In non-human
primates, the dexterity of the paralyzed arm and hand after a
cervical hemisection is almost completely restored by the
intrathecal delivery of a Nogo-A-specific antibody (Freund
et al. 2006, 2009). Fine motor movement recovery is associ-
ated with a large amount of corticospinal axon sprouting past
the lesion site and innervation of the lower cervical cord
segments. The concept of therapeutic antibody administration
in the CNS was first tested in clinical trials targeting Nogo-A;
the anti-human Nogo-A antibody ATI355 produced in collab-
oration with Novartis Pharma (Basel) has recently been estab-
lished as being safe for patients with spinal cord injuries in a
Phase I clinical trial (http://clinicaltrials.gov/ct2/show/
NCT00406016) with 52 acutely injured, severe para- and
tetraplegic patients (Abel et al. 2011). A placebo-controlled
Phase II clinical trial is currently in preparation. In another
CNS disease, amyotrophic lateral sclerosis (ALS), the ectopic
expression of Nogo-A at the neuromuscular junction is an
early sign of the disease and is thought to cause synapse
destabilization and thereby motor control loss (Dupuis et al.
2002; Jokic et al. 2005, 2006). As has been proposed for
spinal cord injury, GlaxoSmithKline (GSK) has developed a
humanized anti-Nogo-A antibody (GSK1223249) to prevent
Nogo-A-induced synaptic destabilization and motoneuron
degeneration in ALS (http://clinicaltrials.gov/ct2/show/
NCT00875446). Preliminary results of a Phase I clinical
trial have recently been presented (Pradat et al. 2011).
Intravenous injections of GSK1223249 appear to be well
tolerated by the 76 patients enrolled in the trial. A larger
Phase II international trial is scheduled for 2012 to assess the
therapeutic benefits of GSK1223249 on ALS symptoms.




Two principal domains of Nogo-A have been shown to exert
inhibitory effects on neurite outgrowth: the Nogo-66 sequence
in the C-terminal RTN region and a 160-aa fragment called
Nogo-A delta20 in the Nogo-A-specific region (Oertle et al.
2003b). A clear mechanism has been elucidated for Nogo-66-
mediated growth inhibition; a receptor complex composed of
the Nogo-66 receptor NgR1, a glycosyl-phosphatidylinositol-
linked leucine-rich repeat protein (Fournier et al. 2001) and
the NgR1-associated proteins Lingo (Mi et al. 2004) and p75
(Wang et al. 2002a) or Troy (Shao et al. 2005) is stimulated by
Nogo-66 leading to the intracellular activation of the RhoA/
ROCK/cofilin pathway that prevents actin cytoskeleton poly-
merization in the growth cone and thereby blocks neurite
extension (Nash et al. 2009; Fig. 1). Consistent with this, in
Nogo-A knock-out (KO) mice, growth cone motility is
increased compared with wild-types (Montani et al. 2009).
Surprisingly, the same receptor complex and downstream
mechanisms seem also to be involved in the growth inhib-
itory effects of other myelin-associated proteins, such as
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myelin-associated glycoprotein (MAG) and oligodendro-
cyte myelin glycoprotein (OMgp) (Wang et al. 2002a). One
way in which myelin-associated inhibitors activate the small
GTPase RhoA might be by the phosphorylation and inactiva-
tion of GSK3beta, thereby allowing CRMP4 and RhoA inter-
action (Alabed et al. 2010).
Another receptor has recently been identified for Nogo-66,
MAG and OMgp, called paired immunoglobulin-like
receptor-B (PirB; Atwal et al. 2008). In primary neuron cul-
tures, the blocking of PirB partially relieves the myelin-
protein-induced inhibition of axonal outgrowth (Atwal et al.
2008). However, the genetic deletion of PirB alone fails to
increase axonal growth in vivo after corticospinal tract tran-
section (Nakamura et al. 2011), traumatic brain lesion (Omoto
et al. 2010), or optic nerve crush (Fujita et al. 2011). As for
NgR1, the regenerative and behavioral outcomes observed
after PirB ablation might depend on the lesioned tract
(Cafferty and Strittmatter 2006) or on (yet unknown) co-
receptors. More work will be necessary to specify the contri-
bution of PirB to the molecular mechanisms underlying axo-
nal regeneration failure in vivo.
The biochemical mechanisms triggered by the Nogo-A
domain Nogo delta20 in neurons remain more elusive. The
receptor(s) bound by Nogo delta20 has(have) not been identi-
fied as yet. However, purified Nogo delta20 has been shown to
destabilize the cytoskeleton, as has been found for Nogo-66, in
a RhoA-dependent manner (Niederost et al. 2002; Joset et al.
2010).
Fig. 1 Molecular mechanisms of Nogo-A-mediated axonal growth
inhibition. a Organization of the growth cone. The growth cone is
composed of a central domain containing the microtubules involved in
the transport of organelles and of a peripheral domain in which actin
filaments (F-actin) form a cytoskeleton meshwork in the lamellipodia
and filopodia. The protrusion of the filopodia occurs at the plus end (+)
of the actin filament and is required to allow the traction of the growth
cone on the extracellular matrix. b Growth cone inhibition. The contact
of filopodial extensions with myelin-associated inhibitors such as
Nogo-A (1) triggers the quick collapse of F-actin in the growth cone
(2). The retrograde signaling is thought to mediate the long-term
effects of Nogo-A on the repression of the neuronal growth program
(3). c Nogo-66 and other myelin inhibitors exhibited at the cell surface
of oligodendrocytes bind to and stimulate a common neuronal receptor
complex. The transduction of the signal passes through the intracellular
activation of the RhoA/ROCK pathway and involves the actin-severing
enzyme cofilin, a main effector in the disassembly of the growth cone
cytoskeleton. Alternatively, the Nogo-A delta20 region is internalized
by an unknown receptor via a pincher-dependent mechanism. The
uptake of Nogo-A delta20 leads to the activation of the RhoA/
ROCK/cofilin cascade. In addition, the resulting molecular complex
can also be retrogradely transported in signalosomes to the neuronal cell
body in which it activates RhoA, negatively regulates phospho-CREB
and thereby attenuates the neuronal growth program (abbreviations are
explained in the text)
Cell Tissue Res (2012) 349:97–104 99
The neuronal growth program
The long-term effects of growth-promoting and growth-
repressing molecules are often regulated at the gene expres-
sion level. Our group has recently demonstrated that growth
cone collapse and RhoA activation require the Pincher-
dependent internalization of Nogo-A delta20 in primary
neurons. In addition to affecting the growth cone cytoskel-
eton assembly, Nogo-A-delta20-containing signalosomes
are retrogradely transported to the cell body in which they
activate RhoA, downregulate cAMP response element-
binding protein (CREB) phosphorylation and repress the
cellular growth program (Joset et al. 2010) (Fig. 1). Inter-
estingly, a similar mechanism of retrograde signaling has
previously been described for neurotrophic factors that exert
opposite growth-promoting effects on axons and that acti-
vate neuronal plasticity (Shao et al. 2002). Strikingly, the
group of Filbin has reported that neurotrophic factors can
overcome myelin-associated protein-mediated growth inhi-
bition by up-regulating cAMP and P-CREB, leading to the
activation of arginaseI expression, a rate-limiting enzyme
for the synthesis of polyamines (Cai et al. 2002; Gao et al.
2004). The signaling of negative and positive regulators of
axonal growth might therefore converge on the same intra-
cellular transcription factors. However, additional molecules
controlling the cellular growth program might be changed
after Nogo-A action, such as the signal transducer and
activator of transcription (Stat; Bareyre et al. 2002) or the
Akt (protein kinase B)-mTOR (mammalian target of rapa-
mycin) pathway. Recent observations suggest that Nogo-A
decreases synaptic protein translation by antagonizing
the mTOR activation required in long-term potentiation
(LTP; Baldwin et al. 2011). The role of those molecules
and pathways remains to be clarified in the CNS (Bareyre
et al. 2011).
At first glance, the presence of two inhibitory active sites
within the Nogo-A sequence seems intriguing. However,
interaction of more than one active site of a signaling
molecule with more than one subunit of a multi-subunit
receptor complex is well known, e.g., for neurotrophic
factors, Wnt, semaphorins, or netrin (Schwab 2010). The
two domains of Nogo-A might differ such that they mediate
plasticity and growth repression. For Nogo-A delta20, short-
and long-term inhibitory mechanisms might operate at the
cytoskeleton and gene expression level, whereas Nogo-66/
NgR1 has been proposed to induce acute growth cone
collapse and neurite growth inhibition but not chronic
outgrowth blockade (Chivatakarn et al. 2007). A bimod-
al functioning of Nogo-A via its two domains activating
distinct receptors or subunits might therefore contribute
to the acute and chronic impairment of axonal plasticity. This
could have relevance for the design of repair strategies for the
lesioned CNS.
Intracellular and endoplasmic-reticulum-associated Nogo-A
Role in survival and axonal regeneration
On the basis of its 200-aa C-terminus, Nogo-A belongs to
the RTN protein family, which is composed of four mem-
bers (RTN1, RTN2, RTN3, RTN4) present in eukaryotes
(Oertle et al. 2003a). Some structural and enzyme regulatory
functions have been described for RTNs; they can influence
the curvature of the endoplasmic reticulum (ER) and appear
as structural regulators for the subcompartment “tubular
ER” (Voeltz et al. 2006). RTNs can also interact with the
anti-apoptotic intracellular proteins Bcl-2 or Bcl-XL and
have therefore been claimed to play a role in cell death
regulation (Tagami et al. 2000; Wan et al. 2007).
In ischemia and after oxidative stress, Nogo-Amight act as a
neuroprotective molecule. After middle cerebral artery occlu-
sion, Nogo-A KO or the acute but not the delayed blockade of
Nogo-A with antibodies decreases neuronal survival (Kilic et
al. 2010). More recently, Nogo-A delta20 transfection in corti-
cal neurons has been shown to protect against hydrogen-
peroxide-induced cell death in vitro, supposedly by interacting
with the enzyme peroxiredoxin 2, which scavenges reactive
oxygen species (Mi et al. 2012).
Nogo-A has been observed to increase in the cell body of
injured neurons suggesting that it exerts cell-autonomous
effects on cell death and/or growth mechanisms (Cheatwood
et al. 2008; Pernet et al. 2011). ER stress is thought to play a
role in many degenerative diseases such as ALS (Atkin et al.
2006; Saxena et al. 2009), Alzheimer’s disease, or Parkinson’s
disease (Doyle et al. 2011). As an RTN protein, the expression
of which can change in compromised neurons, Nogo-A is
suspected of influencing ER stress activation. After optic
nerve injury, we have observed that Nogo-A is up-regulated
in neurons together with other ER-stress-associated markers
such as the pro-apoptotic transcription factor CHOP (Pernet et
al. 2011). However, we have been unable to detect a change in
CHOP expression or in the frequency of apoptosis when
injury-induced Nogo-A is silenced selectively in neurons or
fully deleted genetically. Our results are consistent with pre-
vious in vitro data showing that Nogo-A over-expression does
not enhance the level of CHOP or that of the chaperon protein
Bip (Yang et al. 2009). Therefore, the axon lesion-induced up-
regulation of Nogo-A in neurons does not seem to be an
important regulator of apoptosis in vivo.
Interaction of neuronal Nogo-A with β-secretase (BACE1)
The production of β-amyloid deposits is a hallmark of
Alzheimer’s disease. Interestingly, the group of Yan has
found in vitro that all RTN members including Nogo are
able to bind and to inhibit the β-amyloid-converting enzyme
1 (BACE1), which transforms the amyloid precursor protein
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(APP) into aggregating β-amyloid (He et al. 2004). In vivo,
however, the physiological role of RTNs in this context is
less clear. The over-expression of RTN3 in transgenic mice
reduces the production of β-amyloid in the hippocampus
but concomitantly causes the formation of RTN3 aggregates
in dystrophic neurites (Shi et al. 2009b). The excess of RTN
might compete with APP to bind BACE1, thereby seques-
tering BACE1 in the ER and prevent its enzymatic activity
on APP (Shi et al. 2009b). However, we do not know
whether RTNs and in particular Nogo-A, serve as substrates
for BACE1 and can be secreted, for example, as bioactive
fragments into the extracellular space. In addition, the
experimental over-expression of RTN3 might not faithfully
reproduce pathophysiological conditions such as those
encountered in aging brains (Shi et al. 2009a). Much remains
to be learnt at present on the possible roles of Nogo and RTN
proteins in the regulation of intracellular enzymes such as
BACE1 or of processes such as ER function or cell survival.
The re-formation of functional circuits after traumatic
CNS lesions
Function-blocking antibodies against Nogo-A, NgR1-blocking
peptides, antibodies against Lingo-1, or pharmacological
blockers of the signal transducers RhoA and ROCK have been
applied in various laboratories in spinal cord injury and stroke
models in rats, in mice and, in some instances, also in
monkeys. Enhancement of behavioral recovery in a variety
of sensory-motor tests and enhanced sprouting and long-
distance regeneration of lesioned and spared axons have
been found (Zorner and Schwab 2010). Importantly, a high
degree of similarity is present despite using different ways
to interrupt Nogo-A signaling. Similar but overall weaker
and variable results have been obtained in Nogo KO mice
in spinal cord injury studies (Kim et al. 2003; Simonen et al.
2003; Zheng et al. 2003; Dimou et al. 2006; Cafferty et al.
2010; Lee et al. 2010).
A defined succession of events probably controls the
formation of functional reconnections in the damaged brain
and spinal cord. A time window (1 week in the rat) seems to
exist during which Nogo-A immunotherapy is efficient at
activating spinal cord axon regeneration (Gonzenbach et al.
2012); the treatment with Nogo-A antibody has only weak
behavioral and anatomical effects when delayed by 2 weeks
after the injury compared with the acute or 1-week-delayed
administration. The neuronal growth response occurring
spontaneously after an axonal injury might condition the
effects of Nogo-A neutralization on axonal regrowth. In
the visual system, an intervention window has been defined
in the growth-promoting inflammation paradigm; intra-
ocular inflammation can only elicit axonal regeneration
when the treatment is delivered 3 days before or after optic
nerve crush injury but not after 7 days (Yin et al. 2003). The
time-course of growth-associated-molecule expression has
revealed that, soon after axon transection, neurons attempt
but fail to regenerate. Thus, the neutralization of Nogo-A
might also facilitate the growth of neurons early after injury.
The mechanisms of guidance of regenerating axons in the
adult CNS and the molecular determinants of target recog-
nition have not been studied so far. We do not know whether
sprouts and regenerating axons reconnect to their original
targets in the spinal cord or brain, or whether synapse
formation occurs randomly. Finally, mechanisms of stabili-
zation and pruning of connections and synapses, probably
driven by activity and use, might lead to the formation of
new functional circuits.
Nogo-A is a negative regulator of synaptic plasticity
The expression of Nogo-A in neurons or in glial cells might
also control the formation and stability of synaptic contacts
after a lesion. Most of our knowledge on the effects of Nogo-A
on synaptogenesis and synaptic transmission is derived from a
few developmental studies and from electrophysiological
investigations in the hippocampus. By contrast, little is known
as to the way in which Nogo-A blockade promotes functional
synapses in the adult damaged CNS. Oligodendrocyte-
expressed Nogo-A also acts as a growth-restricting factor in
the developing brain; in the visual cortex, the end of the
activity-driven plastic phase of synapse sprouting, pruning
and stabilization (“critical period”) coincides with the myeli-
nation of layers IV-VI and the expression of Nogo-A. Nogo
restricts the plasticity of the ocular dominance columns in the
adult visual cortex in an NgR1-dependent manner, as shown
by Nogo-KO and NgR1-KO mice analyses. Nogo/NgR1 sig-
naling might therefore be a contributor to the end of the plastic
so-called “critical period” (McGee et al. 2005).
In the adult hippocampus in which synaptic plasticity
remains elevated throughout life, Nogo-A is highly expressed
in pre- and postsynaptic neurons including CA3 and CA1
pyramidal cells (Lee et al. 2008). The addition of function-
blocking anti-Nogo-A antibodies or Nogo-A KO induces
marked changes in the complexity of the basal and apical
dendritic arbors of CA1 and CA3 neurons and leads to massive
sprouting of the CA3 axons (Zagrebelsky et al. 2010). The
proportion of immature spines is also higher in the CA3
neurons. The dendritic and spine phenotypes can be repro-
duced by silencing NgR1 expression. Nogo-A thus appears
here again as a stabilizer of synapses, the suppression of which
leads to growth and higher plasticity in axons and dendrites.
Electrophysiological recordings in acute hippocampal slices
have revealed that the inactivation of Nogo-A or NgR1 with
function-blocking antibodies or KOs increases LTP (Raiker et
al. 2010; Delekate et al. 2011). Whether both neuronal and
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glial Nogo-A influence synapse remodeling and LTP is not
known.
Concluding remarks
Nogo-A appears to be a major inhibitor of axonal regeneration;
it induces the quick destabilization of the actin cytoskeleton
and, on a longer time scale, represses growth gene expression.
Many studies have reported that the neutralization of Nogo-A
or Nogo-A receptor elements restores plasticity, improves
axonal growth and enhances behavioral recovery after injury
with no obvious side-effects. The high significance of these
results has prompted to test the effects of function-blocking
Nogo-A antibodies in patients with spinal cord injuries. Clin-
ical trials are currently ongoing. In contrast, the physiological
role of Nogo-A has been less-well studied. In the intact CNS,
Nogo-A might contribute to stabilizing axonal connectivity
(Park et al. 2010; Schwab 2010). Compelling evidence indi-
cates that Nogo-A also modulates synaptic contacts and neg-
atively influences LTP in the hippocampus. Thus, the
physiological function of Nogo-A in the healthy brain might
be to prevent abnormal sprouting and to regulate the dynamics
of the synaptic cytoskeleton during learning processes. Future
research will help us to understand the way that neuronal and
glial Nogo-A regulates nerve fiber growth and connectivity
and the fine tuning of synaptic plasticity in the developing and
adult CNS.
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